---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/42616800.md"
description: "$ZAI LAB(09688.HK), $CSTONE PHARMA-B(02616.HK) have always had a seat at the table for out-licensing, while $TH MEDICAL-B(02697.HK), $LONGBIO-B(01779.HK), $JIANGXI BIO(06915.HK) — this batch of B-suffix companies are still grinding through clinical trials. As the story of innovative drugs unfolds this year, patience is more valuable than vision 🥲"
datetime: "2026-07-13T10:09:28.000Z"
locales:
  - [en](https://longbridge.com/en/topics/42616800.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/42616800.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/42616800.md)
author: "[逆风执炬](https://longbridge.com/en/profiles/26727938.md)"
generator: "portal-rs"
---

# $ZAI LAB(09688.HK), $CSTONE PHARMA-B(02616.HK) hav…


### Related Stocks

- [02697.HK](https://longbridge.com/en/quote/02697.HK.md)
- [01779.HK](https://longbridge.com/en/quote/01779.HK.md)
- [06915.HK](https://longbridge.com/en/quote/06915.HK.md)
- [09688.HK](https://longbridge.com/en/quote/09688.HK.md)
- [02616.HK](https://longbridge.com/en/quote/02616.HK.md)
- [ZLAB.US](https://longbridge.com/en/quote/ZLAB.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**